Once-Weekly ART Showed Similar Efficacy for HIV as Daily ART
DENVER — A once-weekly oral antiretroviral therapy (ART) regimen of the investigational drug islatravir, a nucleoside reverse transcriptase translocation inhibitor, with lenacapavir (Sunlenca) showed similar efficacy to daily oral ART in people with HIV, a phase II randomized study showed. The virologic suppression rate was 94.2% in both the patients who received the weekly regimen […]